End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.72 CNY | +1.98% | +4.96% | -26.56% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Tires & Rubber Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.56% | 414M | - | ||
+16.92% | 29.95B | A- | ||
+45.11% | 7.05B | C | ||
+25.21% | 4.1B | B+ | ||
-9.46% | 3.61B | B- | ||
-1.54% | 3.6B | C+ | ||
+49.76% | 3.46B | - | - | |
+23.07% | 3.18B | B- | ||
+23.60% | 2.84B | C- | ||
+8.28% | 2.51B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301093 Stock
- Ratings Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.